Share on StockTwits

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Tuesday. The company reported $1.54 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.48 by $0.06, StockRatingsNetwork reports. The company had revenue of $18.10 billion for the quarter, compared to the consensus estimate of $18.00 billion.

JNJ has been the subject of a number of recent research reports. Analysts at Jefferies Group downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday. They now have a $105.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, February 17th. They now have a $97.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $76.92.

Johnson & Johnson (NYSE:JNJ) opened at 97.14 on Tuesday. Johnson & Johnson has a 1-year low of $82.07 and a 1-year high of $99.38. The stock has a 50-day moving average of $94.97 and a 200-day moving average of $92.73. The company has a market cap of $274.8 billion and a price-to-earnings ratio of 20.14. Johnson & Johnson also was the target of a significant increase in short interest in the month of January. As of March 31st, there was short interest totalling 31,078,666 shares, an increase of 9.6% from the March 14th total of 28,349,984 shares. Based on an average trading volume of 10,166,169 shares, the days-to-cover ratio is presently 3.1 days. Currently, 1.1% of the shares of the company are short sold.

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.